Secondary Adjuvant Treatment for Patients With Isolated Tumor Cells in Bone Marrow

PHASE2CompletedINTERVENTIONAL
Enrollment

1,128

Participants

Timeline

Start Date

October 31, 2003

Primary Completion Date

November 30, 2012

Study Completion Date

April 30, 2022

Conditions
Breast Cancer
Interventions
DRUG

Docetaxel

Docetaxel 100 mg/m2 3 qw x 6

Trial Locations (1)

0027

RRHF, Oslo

All Listed Sponsors
collaborator

University of Tromso

OTHER

collaborator

Helse Stavanger HF

OTHER_GOV

collaborator

Sorlandet Hospital HF

OTHER_GOV

collaborator

Sykehuset Innlandet HF

OTHER

collaborator

Ullevaal University Hospital

OTHER

collaborator

Sykehuset i Vestfold HF

OTHER

collaborator

Sykehuset Ostfold

OTHER

collaborator

Alesund Hospital

OTHER

lead

Oslo University Hospital

OTHER

NCT00248703 - Secondary Adjuvant Treatment for Patients With Isolated Tumor Cells in Bone Marrow | Biotech Hunter | Biotech Hunter